Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma
Autore:
Phan, GQ; Attia, P; Steinberg, SM; White, DE; Rosenberg, SA;
Indirizzi:
NCI, Surg Branch, NIH, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Surg Branch, NIH, Bethesda, MD 20892 USA NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892 ta Management Sect, NIH, Bethesda, MD 20892 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 15, volume: 19, anno: 2001,
pagine: 3477 - 3482
SICI:
0732-183X(20010801)19:15<3477:FAWRTH>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED KILLER-CELLS; RECOMBINANT INTERLEUKIN-2; ADOPTIVE IMMUNOTHERAPY; BOLUS INTERLEUKIN-2; THYROID-DYSFUNCTION; MALIGNANT-MELANOMA; ADVANCED CANCER; VITILIGO; CARCINOMA; INFUSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Rosenberg, SA NCI, Surg Branch, NIH, Bldg 10,Rm 2B42,9000 Rockville Pike, Bethesda, MD 20892 USA NCI Bldg 10,Rm 2B42,9000 Rockville Pike Bethesda MD USA 20892
Citazione:
G.Q. Phan et al., "Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma", J CL ONCOL, 19(15), 2001, pp. 3477-3482

Abstract

Purpose: The present study attempted to identify characteristics that correlated with clinical response to interleukin (IL)-2 therapy in patients with metastatic melanoma. Patients and Methods: We retrospectively evaluated laboratory and clinicalcharacteristics of 374 consecutive patients with metastatic melanoma treated with high-dose intravenous bolus IL-2 (720,000 IU/kg) from July 1, 1988,to December 31, 1999, at the Surgery Branch of the National Cancer Institute. Results: The overall objective response rate was 15.5%. Pretreatment parameters such as patient demographics, laboratory values, and prior therapy did not correlate with response; however, 53.6% of patients with only subcutaneous and/or cutaneous metastases responded, compared with 12.4% of patients with disease at other sites (P-2 = .000001). During therapy, patients whowere responders tended to have received more doses during course 1 (16.2 +/- 0.3 doses v 14.5 +/- 0.2 doses; P-2 = .0095); however, when limited to patients who were able to complete both cycles of course 1, there was no statistically significant difference (P-2 = .27). Responders had a higher maximum lymphocyte count immediately after therapy compared with nonresponders (P-2 = .0026). The development of abnormal thyroid function tests and vitiligo after therapy was associated with response (thyroid-stimulating hormone, P-2 = .0 1; free T4, P-2 = .0049; vitiligo, P-2 < 10(-6)), although thyroid dysfunction may have been related more to the length of IL-2 therapy than to response. Conclusion: The presence of metastases only to subcutaneous and/or cutaneous sites, lymphocytosis immediately after treatment, and long-term immunologic side effects, especially vitiligo, were associated with antitumor response to IL-2 therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 10:55:26